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Common variable immunodeficiency (CVID) is the most common primary
immunodeficiency in adults. It is associated with hypogammaglobulinemia, recurring
infections and autoimmune phenomena. Treatment includes immunoglobulin substitution
and immunosuppressants. Autoimmune neurological manifestations of CVID are rare
and occur predominantly as granulomatous disease. We report the case of a 35-year-old
woman with CVID who developed autoimmune encephalitis as demonstrated by double
cerebral biopsy. Infectious or malignant causes could be excluded. Despite intensive
immunosuppressive therapy with common regimens no significant improvement could
be achieved. Ultimately, an autologous hematopoietic stem cell transplantation (HSCT)
was performed, resulting in lasting complete remission of the encephalitis. To our
knowledge, this is the first report of refractory autoimmune phenomena in CVID treated
by autologous HSCT.
Keywords: common variable immunodeficiency, primary immunodeficiencies, autoimmunity, autologous stem cell
transplantation, autoimmune encephalitis
INTRODUCTION
Common variable immunodeficiency (CVID) is the most common primary immunodeficiency in
adults. The primary finding is hypogammaglobulinemia (1). Clinical symptoms are heterogeneous
with different levels of immune dysregulation (2). In addition to infectious complications,
autoimmune manifestations, including immune cytopenias, pneumonia, inflammatory bowel
disease, and granulomatous inflammation, occur in about 20% of cases (3). Central nervous system
(CNS) involvement is rare in CVID; most data are found for cerebral granulomatous disease (4),
one case reported unilateral optic neuritis (5). Management of CVID includes immunoglobulin
replacement (IgRT), immunosuppressive therapy for autoimmune manifestations, and close
surveillance for the development of additional comorbidities (2). In this case report, we present
a young woman with CVID who developed autoimmune CNS involvement, comprising brain and
spinal cord. To our knowledge, this is one of very few cases reporting non-granulomatous CNS
involvement. In addition, this is the first case demonstrating the effective and safe performance
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of autologous HSCT as treatment of a severe, organ-threatening,
refractory autoimmune manifestation in CVID.
CASE PRESENTATION
A 35-year-old woman was admitted at our hospital for pleural
empyema. Primary antibiotic treatment was followed by surgical
removal of the affected lung sub-segment. Histology showed
a fibrosing reaction with histological pattern of non-specific
interstitial pneumonia (NSIP), as well as typical infectious
features. Since adolescence, the patient suffered from recurring
respiratory infections. At the age of 15, she developed immune
thrombocytopenia, which was successfully treated with several
cycles of intravenous immunoglobulins. In her early 30s, she
twice suffered from herpes zoster reactivation.
Further examination revealed splenomegaly, abdominal
lymphadenopathy, and decreased serum immunoglobulin levels.
According to the guidelines of the European Society for
Immunodeficiencies (ESID) (6), diagnosis of CVID could be
made. Total immunoglobulin values at diagnosis were IgG 598
mg/dl, IgA < 5 mg/dl, IgM 27 mg/dl. The lymphocyte count
was reduced (760/µl) with low levels of CD4+ T-helper cells
(234/µl), reduced naïve CD4+ T-helper cells (11,2% of all CD4+
T-cells), but immunophenotyping showed a normal percentage
of NK cells, T-cells and B-lymphocytes with disturbedmaturation
and reduction of switched memory B-cells and an increase
in CD21 low B-cells, which according to the classification for
immunodeficiencies (EUROclass) corresponds to the following
subgroup: smB- TRhigh CD21low (7). Due to the low T-cell
count, classification as a combined Immunodeficiency (CID)
would also have been possible. Furthermore the patient displayed
a decreased frequency of regulatory T cells (Treg) which also
indicated a dysfunctional phenotype with low expression of
CTLA4 (cytotoxic T-lymphocyte-associated Protein 4) as well
as FOXP3 (Supplemental Figure 1). Molecular genetic testing
for typical genetic defects in CVID such as LRBA, CD3G,
IL2RA, LAT, LCK, PIK3CD, PIK3R1, PTEN, STAT3, ZAP70, or
CTLA4 deficiency, yielded no results. Other causes of secondary
hypogammaglobulinemia, such as HIV, were excluded. No
lymphoma was found by bone marrow trephine biopsy or total
body CT scan.
The patient recovered well under antibiotic therapy.
Immunoglobulin replacement therapy (IgRT) with subcutaneous
immunoglubulins (0.5 g/kg body weight every 4 weeks combined
with hyaluronidase, target trough level of 6 g/l) was initiated.
Despite stable clinical representation, a chest CT scan 2 months
later showed progressive infiltrates of the lung parenchyma,
as well as bronchiectasis. To rule out a new infection, a
bronchoscopy was performed, which showed no evidence of
bacterial or mycotic infection, including TB. Virus PCR for EBV,
CMV, and common respiratory tract infections was negative.
We therefore considered the infiltrates a manifestation of
CVID, most likely as granulomatous-lymphocytic interstitial
lung disease (GLILD), and started immunosuppressive therapy
with prednisolone (1 mg/kg) and subsequent taper, and
azathioprine (2.5mg/kg/day). A CT scan 6months later showed a
FIGURE 1 | Hyperintense lesion with perifocal edema left occipital in
fluid-suppressed T2 MRI technique (Fluid-attenuated inversion recovery
(FLAIR) sequence).
significant improvement of the pulmonary infiltrates, the patient
had no relevant infections since starting IgG substitution.
4 months later the patient suffered a generalized epileptic
seizure. Cerebral MRI showed several periventricular,
subependymal, and leptomeningeal lesions with intensive
contrast medium uptake. The criteria for multiple sclerosis were
not met on the basis of the distribution pattern and a pattern
of different ages of lesions. The largest lesion was located in
the left posterior lobe with a diameter of 4.4 cm (Figure 1).
CSF analysis showed a mild pleocytosis with a normal protein
content. Oligoclonal bands were not detectable. A eubacterial
16S rRNA PCR was negative, as were PCRs for HSV, VZV, EBV,
CMV, HHV6, HHV7, HHV8, adenovirus, enterovirus, BK virus,
and JC virus.
We proceeded to biopsy the occipital lesion by stereotactic
puncture. The histological examination showed an inflammation
with predominantly perivascular accumulation of T-lymphocytes
and an increase in plasma cells without kappa/lambda light
chain restriction. Malignant cells, granulomas, or demyelinating
plaques were not detected. Hence, the etiology remained unclear.
Another whole-body CT scan as well as a further bone marrow
trephine biopsy did not show any pathological findings. Due
to the lack of clarity and the therapeutic relevance, a second
stereotactic biopsy was performed. This second tissue sample was
sent to the German Reference Laboratory for Neuropathology.
Again, no signs of malignancy were found, as well as no evidence
of infection or demyelination, the pattern of T-cell predominant
perivascular lymphocytic infiltration was confirmed. Thus, the
histological findings as well as the other previous findings
were compatible with an autoimmune encephalitis. Important
differential diagnoses like lymphoma or multiple sclerosis
were excluded.
In addition to IgRT, we started a more intensive
immunosuppressive therapy with 2 cycles of rituximab 1,000mg
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FIGURE 2 | Hyperintense lesions in medulla oblongata and in cervical and
upper thoracic spinal cord in contrast enhanced, fat suppressed T1
MRI technique.
i.v. and high-dose steroids (prednisolone ∼1.5 mg/kg/day)
with subsequent taper. An MRI control of the CNS a few
weeks later showed receding lesions. The patient’s condition
was stable with additional administration of an anticonvulsant
and azathioprine as maintenance therapy. However, under
the dose of azathioprine 2.5 mg/kg/day and prednisolone
15 mg/day, another MRI control 2 months later showed a
renewed increase in intracerebral inflammatory activity with
progressing lesions. Immunosuppressive therapy was escalated
using cyclophosphamide (750 mg/m2 iv every 3 weeks),
with additional trimethoprim/sulfamethoxazole prophylaxis.
Azathioprine was discontinued. A staging MRI 3 cycles of
cyclophosphamide showed a mixed response. New lesions were
found in the medulla oblongata and in the posterolateral cervical
medulla. MRI of the entire spinal cord showed focal lesions in
the cervical and thoracic myelon extending to the Th2 segment
(Figure 2). The clinical examination was inconspicuous, with no
evidence of neurological symptoms.
We initiated therapy with abatacept, a T cell activation
modulator 14 mg/kg bw i.v. (week 0, 2, then every 4 weeks), also
due to the known Treg CTLA4 deficiency. In addition, a high-
dose therapy with steroids (prednisolone 1,000mg for 3 days)
with subsequent dose reduction to 1 mg/kg body weight and then
further tapering was performed. Again, MRI control of the CNS
and spinal cord after initial improvement showed progression 3
months after starting abatacept.
Up to this point, no treatment regime had led to a sustained
improvement in cerebral or spinal inflammation. The diagnosis
underwent a critical review, including renewed CT, CSF analysis,
and infection screening. No new findings were made. A further
biopsy was not performed.
Due to the organ-threatening character of the inflammatory
activity, which could not be controlled despite the previous
intensive immunosuppression, we saw an autologous stem
cell transplantation as the best possibility to intensify the
therapy. Other therapy options did not seem promising in
this situation. We used a well-established protocol according
to the guidelines of European Group for Blood and Marrow
Transplantation (EBMT). For mobilization of autologous
hematopoietic stem cells, the patient received cyclophosphamide
2 g/m² together with a daily dose of 105 µg G-CSF, starting
on the second day after cyclophosphamide administration.
Leukapharesis was performed on day 10. The autologous
hematopoietic stem cells underwent CD34+-selection using
immunomagnetic separation (CliniMACS CD34 Complete Kit,
Miltenyi Biotec, Bergisch Gladbach, Germany). 8 weeks after
apheresis, conditioning with cyclophosphamide (4 × 50 mg/kg
body weight) and rabbit antithymocyte globulin (rATG) (3 ×
5 mg/kg body weight) was administered over 5 days. On day 1
after conditioning, the autologous graft was transplanted (2.6
× 106 CD34+ cells/kg body weight). During the subsequent
aplasia phase until engraftment, the patient had several
typical adverse events. Due to thrombocytopenia a small,
non-significant subdural hematoma occurred. Substitution
of 2 platelet concentrates stabilized hemostasis sufficiently.
In addition, 2 red cell concentrates were given due to severe
anemia. Apart from sinusitis, which was treated with antibiotics,
no relevant infectious complications occurred. The patient
received oral acyclovir and posaconazole prophylaxis. IgRT
was continued unchanged to keep immunoglobulin levels
stable within target range (6 g/l). Recovery of neutrophils
above 500/µl occurred on day 14 after transplantation.
Lymphocyte counts remained low at 700/µl on day 30.
However, rather low values had already been measured before
transplantation, probably because of the CVID itself, or due
to immunosuppressive therapy. As was to be expected, the
number of CD4+ T-helper cells was significantly reduced after
transplantation (52/µl on day). On the day of discharge a low
dose of prednisolone (10 mg/day) was maintained, as well as
prophylactic oral therapy with trimethoprim/sulfamethoxazole,
oral amphotericin B, and acyclovir. A CNS-MRI 3 weeks after
discharge showed a significant decrease in intracerebral and
intraspinal inflammation. Further controls after 3, 7, and 12
months showed a complete disappearance of the lesions. The
health condition of the patient improved steadily. Regular
controls of the immune reconstitution by immunophenotyping
showed a gradual increase of T cells and B cells in the following
months. After 11 months the CD4+ T helper cells reached
200/µl, so that acyclovir and amphotericin B were discontinued,
trimethoprim/sulfamethoxazole was continued. As a sign of
increased plasma cell activity during reconstitution there was an
increase in polyclonal IgM. We decided to administer rituximab
as B cell depleting maintenance therapy (1,000mg, day 0, 15).
The first cycle was given 9 months after transplantation, a second
cycle 6 months later, resulting in a complete depletion of B
cells and a decrease in IgM. Prednisolone was reduced to a
minimal dose of 2.5 mg/day. 18 months after transplantation
the patient is in good health without autoimmune symptoms,
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regular MRI controls show a sustained remission. Under
persistent IgRT no severe infection has occurred since
transplantation. The patient resumed her daily activities and her
former profession.
DISCUSSION
We present a case of a female patient (35) with autoimmune
encephalitis as a CNS manifestation of CVID, which was
successfully treated by immunoablative conditioning and
transplantation of autologous CD34-selected stem cells.
CNS involvement in CVID is rare, especially in the form
of autoimmune encephalitis (4). It is therefore of utmost
importance to distinguish between an autoimmune CVID
manifestation of the CNS and differential diagnoses, especially
cerebral lymphoma or infectious complications, as far as possible.
This was done in our patient by repeated imaging, two biopsies
and extensive testing of CSF.
There is increasing evidence that, in addition to B cell
dysfunction, T cell dysfunction plays an important role in
autoimmunity in CVID (8). In a large cohort, it was shown
that total T cells in CVID patients with autoimmune symptoms
were lower than in those without autoimmunity (9). The degree
of reduction of CD4+ T cells correlates with the severity of
autoimmune symptoms (10, 11). Within the CD4+ T cells,
a reduced number of regulatory T cells is associated with
autoimmunity in CVID (12). Our patient showed normal total
T cells, however, a reduced expression of the T cell surface
protein CTLA4 on T reg could be detected as surrogate
of disturbed T reg function (13). Mutations of CTLA4 are
common in CVID patients and are associated with autoimmunity
through the disruption of self-tolerance regulation (11). Based on
these findings, our patient was treated with abatacept, a T-cell
activation modulator, which has been shown to be effective in the
treatment of other syndromes associated with CTLA4 deficiency
(14). In this patient, abatacept was ineffective.
The most intensive form of therapy for primary
immunodeficiencies (PID) is allogenic stem cell transplantation.
Since most forms of PID are based on monogenetic defects
intrinsic to hematopoietic cells (15), the treatment of primary
immunodeficiency by replacing the mutated cells with healthy
donor hematopoietic stem cells and establishing alloimmunity
is a potentially curative approach. Based on proper strategies in
selection of a suitable donor (16–19) and GvHD prophylaxis,
reduced intensity conditioning regimes (20) and better
supportive care overall survival reaches up to 85% today
even for patients who undergo transplantation in young
adulthood (21).
The role of allogeneic stem cell transplantation in CVID is
controversial. Wehr et al. (22) showed results of a retrospective
evaluation of 25 patients who underwent allogeneic stem cell
transplantation for CVID. The indication was mainly based on
the presence of immune dysregulation and not on infections.
However, the mortality rate of CVID patients was 52% after
allogeneic HSCT, which is significantly higher than for other PID.
The main causes were treatment-resistant graft-vs.-host disease
and infectious complications. On the other hand, survivors no
longer needed IgRT in 50% of cases, and in 92% of surviving
patients, health complaints that were the indication for allogeneic
stem cell transplantation were significantly improved.
Autologous stem cell transplantation aims to “reset” the
immune system by eradicating the autoreactive immunological
memory. In contrast to allogeneic stem cell transplantation,
transfusion of the patient’s own stem cells does not generate
alloimmunity. Immuno-ablative therapy and transfusion of
CD34-selected stem cells causes a profound regeneration of the
adaptive immune system with lasting changes in T-cell and
B-cell subpopulations from memory to naive cell dominance
(23, 24). The transplantation leads to a renewal of naive T cells
including regulatory T cells via reactivation of the thymus (25).
Furthermore, a diversification of the T cell receptor repertoire
can be observed (26, 27). This can only be partially seen in our
patient so far: While there was a normalization of natural killer
cells within 6 months after transplantation, a persistent reduction
of T cells was also detectable 18 months after the procedure with
low levels of naïve CD4+ T cells. Delayed repopulation of naive
CD4+ T lymphocytes was seen in several studies up to 24months
after transplantation (28–30) and correlated with an increase in
TCR excision circles (TREC) (31, 32), which serve as a surrogate
for increased biosynthesis of the T cell receptor (33, 34).
In this context it could also be shown that TREC levels
were higher in autologous stem cell transplantation when
a CD34+ selection of the transplant was performed (25).
However, the role of CD34+ selection in SCT of autoimmune
diseases is controversially discussed. A retrospective analysis
of autoimmune patients in the European Bone Marrow
Transplantation Database (EBMT) did not show an
improvement of response using CD34+ selected grafts (35).
A randomized study on CD34+ selection in autologous stem
cell transplantation in patients with rheumatoid arthritis did
not show any benefit in the outcome (36), nor did a recent
retrospective study evaluating CD34+ selection in systemic
sclerosis (37). On the other hand, it is considered that the return
of a lymphocyte-depleted transplant results in the most complete
eradication of autoreactive T cell clones, which is the basis for
a stable, long-lasting remission. This hypothesis is supported
by studies in multiple sclerosis patients who received a CD34+
selected autologous stem cell transplant and subsequently had
no evidence of new inflammatory activity for up to 13 years
after treatment (38). In addition, a prospective evaluation
of the EBMT on patients with systemic sclerosis could now
demonstrate a benefit of CD34+ selection in autologous stem
cell transplantation in terms of outcome, which could possibly be
due to the now more homogeneous conditioning regimen (39).
A Japanese study recently showed similar results (40).
One of the main indications for autologous stem cell
transplantation in autoimmune diseases today is multiple
sclerosis (MS) (35), which is also an autoimmune cerebral
inflammation. In contrast to CVID, several studies have
already well investigated the effectiveness of autologous stem
cell transplantation on MS (41). In a meta-analysis of 280
patients who received autologous stem cell transplantation, the
overall survival rate was 93% after 5 years (42). Depending
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on the different subtypes of the disease, a progression-
free survival in terms of a deterioration of the Expanded
Disability Status Scale (EDSS) of up to 73% after 5 years
was achieved. Similar to the analysis of Wehr et al. on
allogeneic transplantation, a higher age, the number of previous
therapies and the intensity of the conditioning regimen
were predictors of a worse outcome. Despite several pre-
treatments, the good response of our patient is thus possibly
favored by the young age and the only minor chronic
organ damage.
Taken together, good results on the effectiveness in refractory
autoimmune diseases, and the excellent control of infectious
risk by IgRT in this patient, made us favor autologous against
allogeneic SCT as a treatment option.
So far, there are no guidelines for the therapeutic procedure
after successful transplantation of autoimmune diseases, the role
of immunosuppressive maintenance therapy was not examined
in studies yet and remains controversial. In our patient,
IgRT was continued unchanged. Maintenance treatment with
rituximab was established due to possibly severe consequences
of a relapse and signs of transient excessive B cell activation
after SCT.
CONCLUSION
Autologous hematopoietic stem cell transplantation can be a
highly effective therapy for the treatment of severe refractory
autoimmune manifestations of CVID. In the present case, it
has been shown to induce sustained remission in the rare
and life-threatening case of autoimmune encephalitis. Since
autoimmunity is also the indication for transplantation in most
cases in allogeneic stem cell transplantation in CVID, autologous
transplantation could be a viable alternative for the treatment
of these patients, considering the high periprocedural morbidity
and mortality of allogeneic transplantation in CVID to date.
However, the management of the therapy requires a high level
of expertise, and studies on larger collectives would therefore be
highly desirable.
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Supplemental Figure 1 | Disturbed phenotype of regulatory T cells. Frequency of
CD25+CD127-FOXP3 regulatory T cells (Treg) within CD4+ T cells (A),
fluorescence intensity (MFI) of FOXP3 expression in CD25+CD127-CD4+ T cells
(B), as well as ratio of CTLA4 expression between CD45RO+ Treg and
CD45RO-CD25+/-CD127+FOXP3- naïve conventional T cells (Tcon) of healthy
control individuals (Co) and the patient (C). The 10th and 90th percentile of each
parameter within the group of control indivdiuals is shown as dashed lines. The
expression of FOXP3 in CD4+CD25+CD127- T cells of the patient and a healthy
control is shown in (D). The expression of CTLA-4 in CD45RO+ Treg and
CD45RO- Tcon of the patient and a healthy control is shown in (E).
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